Abstract: The disclosure relates to a modified adeno-associated virus (AAV) vector for treating various pathologies. The modified AAV vector may include transfected Claudin genes for use in treating those pathologies via the disclosed gene therapy. The disclosure also relates to the methods of preparing, administering, and testing the disclosed genetic therapies. Furthermore, the disclosure relates to systems and methods for monitoring, locally or remotely, a patient's medical condition and the efficacy of an administered genetic therapy. The system and methods also disclose adjusting the genetic therapies based on established operating parameters.

Abstract: The disclosure relates to an effervescent therapeutic composition for delivering multiple compounds to a patient in a single administration. In some embodiments, the effervescent therapeutic composition includes an alkaline effervescing compound, one or more compressible binders, a pharmaceutically acceptable salt of metformin, a pharmaceutically acceptable cobalamin, and an acid compound or an acid salt. In other embodiments, the effervescent therapeutic composition may include a folate or folic acid and metformin. In yet other embodiments, the effervescent therapeutic composition may include a folate or folic acid, cobalamin, and metformin.